BC
TEVA icon

Broadfin Capital’s Teva Pharmaceuticals TEVA Stock Holding History

Broadfin Capital’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-4,000
Closed -$210K – 77
2014
Q2 		$210K Buy
+4,000
New +$204K 0.02% 69

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Barrow, Hanley, Mewhinney & Strauss
Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
HCM
Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
NC
Northern Cross Boston, Massachusetts $279M AUM 1.98% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Broadfin Capital's TEVA Position: Q1 2017 in Review

Broadfin Capital sold out of Teva Pharmaceuticals (TEVA) in Q1 2017, closing a stake of 647,500 shares — an estimated $23.5M sold.

Broadfin Capital first reported a position in TEVA in Q2 2013 and held it in 6 quarters. The position peaked at $33.8M in Q2 2013. 686 funds tracked by Wall St. Rank hold TEVA as of Q1 2017.

  • Broadfin Capital reported no remaining Teva Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
  • Broadfin Capital sold 647,500 Teva Pharmaceuticals shares in Q1 2017, an estimated $23.5M.
  • Broadfin Capital first reported a position in Teva Pharmaceuticals in Q2 2013 and held it in 6 quarters.
  • Broadfin Capital's Teva Pharmaceuticals position peaked at $33.8M in Q2 2013.
  • 686 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2017.

Based on Broadfin Capital's 13F filing for Q1 2017, filed 15 May 2017.